Renal cell carcinoma (RCC):
An amazing story of improved outcomes
Cora Sternberg, MD, FACP
San Camillo-Forlanini Hospital
Rome, Italy

Building on a solid base of targets and targeted agents in RCC
Bernard Escudier, MD (Chair)
Institut Gustave Roussy
Paris, France

Dealing with unmet needs in RCC in the
s new era of targeted therapy
Peter Mulders, MD, PhD
Radbound University Nijmegen
Medical Centre
The Netherlands

Promising developments for castration-refractory prostate cancer (CRPC)
Johann Sebastian de Bono, MD, FRCP, MSc, PhD
Royal Marsden Hospital
London, United Kingdom